EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities

Pingping Yang iD, Jun Ren iD, Lifang Yang iD

International Journal of Molecular Sciences · 08.03.2023 · 24 (6) · 5205

DOI: 10.3390/ijms24065205 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.03.2023. Verfasst von Pingping Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Xi'an Children Hospital, Xi'an 710032, China. Hauptthemen laut MEDLINE: Myocardial Infarction, Cardiovascular Diseases, Atherosclerosis, Cardiovascular System. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Outstanding Youth Foundation of Shaanxi Province, Xi’an Talent Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Although a cadre of therapeutic strategies have been made available for CVDs in the clinical setting, predominantly through medication and surgery, these do not fully address the clinical needs of patients with CVD. As a new technique for CVD treatment, nanocarriers are employed to modify and package medications to ease the targeting of tissues, cells and molecules within the cardiovascular system. Nanocarriers are made of biomaterials, metals, or a combination of these materials, with sizes similar to bioactive molecules such as proteins and DNA. Cardiovascular nanomedicine (CVN) has only surfaced in recent years and is still in its infancy. Ample studies have displayed promise for the clinical utility of nanomedicine techniques, courtesy of continued perfection in nanocarrier design to optimize drug delivery and treatment outcomes. Here in this review, we will summarize the research advances in the literature on nanoparticles in the management of CVDs, including ischemic and coronary heart disease (e.g., atherosclerosis, angina pectoris and myocardial infarction), myocardial ischemia-reperfusion injury, aortic aneurysm, myocarditis, hypertension, and pulmonary artery hypertension and thrombosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial InfarctionCardiovascular DiseasesAtherosclerosisCardiovascular SystemNanoparticlesHypertensionHumans

Stichwörter der Autor:innen

cardiovascular diseaseischemia-reperfusion injuryischemic heart diseasenanoparticletherapy

Autor:innen und Institutionen

  • Department of Anesthesiology, Xi'an Children Hospital, Xi'an 710032, China.
  • Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai 200032, China.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
  • Key Laboratory of Precision Medicine to Pediatric Diseases of Shaanxi Province, Xi'an 710003, China.

ORCID-Profile: Pingping Yang, Jun Ren, Lifang Yang

Förderung

  • National Natural Science Foundation of China
  • Outstanding Youth Foundation of Shaanxi Province
  • Xi’an Talent Program

Zitieren

APA

Yang, P., Ren, J., & Yang, L. (2023). Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities. International Journal of Molecular Sciences, 24(6), 5205. https://doi.org/10.3390/ijms24065205

Vancouver

Yang P, Ren J, Yang L. Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities. International Journal of Molecular Sciences. 2023;24(6):5205. doi:10.3390/ijms24065205

BibTeX
@article{Yang2023,
  author = {Yang, Pingping and Ren, Jun and Yang, Lifang},
  title = {Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {6},
  pages = {5205},
  doi = {10.3390/ijms24065205}
}
Kostenlos starten →